Profile data is unavailable for this security.
About the company
Eris Lifesciences Limited is an India-based company that is primarily engaged in the manufacturing and marketing of pharmaceutical products. The Company’s manufacturing plant is located in Guwahati, Assam. Its therapeutic areas include oral diabetes care, cardiac care, pain/analgesics, gynecology, gastrointestinal, central nervous system (CNS), and vitamins, minerals, and nutrients (VMN). The Company's brands include Advog 0.2, Atorsave Gold 10, Baga NT 100, Calshine 60K Tablet, Carpela, Cilentra Plus 5, Cognix, D1000cal, Enoxsave 60, Glimisave M 4 forte, Levroxa 1000, Mac Rabonik Plus, Glimisave, Eritel, Renerve, Tendia, Olmin, Rabonik, Tayo, Cyblex, Lnbloc, Remylin, Zomelis, Crevast, Atorsave, Ginkocer and Metital. The Company’s wholly owned subsidiaries include Kinedex Healthcare Private Limited, Aprica Healthcare Limited, and Eris Healthcare Private Limited.
- Revenue in INR (TTM)20.09bn
- Net income in INR3.92bn
- Incorporated2007
- Employees3.55k
- LocationEris Lifesciences Ltd7th Floor, Commerce House IV,,Beside Shell Petrol Pump, 100 Feet Road,AHMEDABAD 380054IndiaIND
- Phone+91 7 969661000
- Fax+91 7 930179404
- Websitehttps://eris.co.in/
Mergers & acquisitions
Acquired company | ERIS:NSI since announced | Transaction value |
---|---|---|
Biocon Biologics Ltd-BFI Business | 9.19% | 149.96m |
Swiss Parenterals Ltd | 0.57% | 76.84m |
Biocon Biologics Ltd - Dermatology And Nephrology Business Units | 4.97% | 43.98m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Blue Jet Healthcare Ltd | -100.00bn | -100.00bn | 65.80bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 5.49 | -- | -11.88 | -- | -- | -- |
Sun Pharma Advanced Research Co Ltd | 755.50m | -3.87bn | 70.71bn | 407.00 | -- | 56.23 | -- | 93.60 | -11.93 | -11.93 | 2.33 | 3.87 | 0.1123 | -- | 3.13 | -- | -57.57 | -61.70 | -85.93 | -119.31 | 62.77 | 76.08 | -512.52 | -163.40 | -- | -245.33 | 0.3414 | -- | -68.36 | -16.20 | -73.96 | -- | 15.40 | -- |
Marksans Pharma Ltd | 21.03bn | 3.17bn | 74.66bn | 1.40k | 23.37 | -- | 19.29 | 3.55 | 7.05 | 7.05 | 46.71 | -- | -- | -- | -- | 15,024,090.00 | -- | 14.78 | -- | 19.58 | 51.88 | 50.16 | 15.21 | 13.01 | -- | 44.45 | -- | 5.49 | 24.23 | 15.20 | 44.29 | 51.89 | 6.61 | 58.49 |
F D C Ltd | 19.16bn | 2.90bn | 75.59bn | 6.37k | 26.34 | -- | 23.00 | 3.95 | 17.63 | 17.63 | 116.59 | -- | -- | -- | -- | 3,006,457.00 | -- | 11.68 | -- | 13.29 | 65.72 | 62.03 | 15.11 | 15.85 | -- | 70.61 | -- | 1.22 | 16.74 | 10.49 | -10.34 | 2.26 | 25.03 | -- |
Strides Pharma Science Ltd | 40.51bn | -1.25bn | 78.04bn | 2.85k | -- | 3.67 | 108.17 | 1.93 | -13.86 | -7.93 | 445.06 | 231.29 | 0.6493 | 1.44 | 3.32 | -- | -2.38 | -1.68 | -4.43 | -2.97 | 59.50 | 52.74 | -3.67 | -3.36 | 0.64 | 1.07 | 0.5485 | -- | 9.83 | 13.21 | 43.57 | -- | -18.52 | -3.58 |
Procter & Gamble Health Ltd | 11.69bn | 2.14bn | 79.90bn | 1.41k | 37.36 | -- | 33.19 | 6.84 | 128.85 | 128.85 | 703.49 | -- | -- | -- | -- | 8,305,331.00 | -- | -- | -- | -- | 70.45 | -- | 18.31 | -- | -- | 400.33 | -- | -- | 10.34 | -- | 19.19 | -- | -- | -- |
Neuland Laboratories Ltd. | 15.59bn | 3.00bn | 81.18bn | 1.57k | 27.05 | 6.33 | 22.56 | 5.21 | 233.89 | 233.89 | 1,214.80 | 999.78 | 0.9135 | 2.33 | 4.24 | -- | 17.59 | 9.25 | 23.58 | 12.71 | 52.92 | 47.21 | 19.25 | 11.99 | 1.33 | 28.78 | 0.0692 | 7.13 | 30.84 | 18.51 | 83.51 | 78.76 | 17.88 | 63.45 |
Wockhardt Ltd | 27.76bn | -5.01bn | 86.01bn | 2.74k | -- | -- | -- | 3.10 | -34.79 | -34.79 | 192.79 | -- | -- | -- | -- | 10,131,390.00 | -- | -4.12 | -- | -7.34 | 57.60 | 53.98 | -19.16 | -10.98 | -- | -0.1981 | -- | -- | -17.93 | -7.60 | -129.10 | -- | -7.43 | -- |
Caplin Point Laboratories Ltd | 16.94bn | 4.57bn | 98.28bn | 777.00 | 21.60 | 4.24 | 19.09 | 5.80 | 59.90 | 59.90 | 222.01 | 304.93 | 0.6931 | 2.22 | 3.62 | -- | 18.88 | 19.83 | 21.80 | 22.82 | 57.25 | 53.99 | 27.24 | 25.39 | 4.63 | 976.47 | 0.0008 | 7.86 | 15.50 | 21.17 | 21.48 | 20.95 | 17.47 | 2.59 |
Glenmark Life Sciences Ltd | 22.83bn | 4.71bn | 101.94bn | 1.82k | 21.68 | 4.37 | 19.44 | 4.46 | 38.38 | 38.38 | 186.08 | 190.35 | 0.8224 | 1.58 | 2.90 | -- | 16.96 | 18.28 | 20.43 | 30.03 | 56.11 | 53.40 | 20.62 | 20.23 | 2.85 | 401.55 | 0.0073 | -- | 5.64 | 20.83 | 0.841 | 19.21 | 69.11 | -- |
Granules India Ltd | 45.06bn | 4.05bn | 106.32bn | 3.65k | 26.22 | 3.30 | 17.35 | 2.36 | 16.73 | 16.73 | 186.06 | 133.08 | 0.8645 | 1.65 | 4.66 | -- | 7.78 | 10.68 | 12.41 | 16.18 | 55.15 | 51.39 | 8.99 | 11.82 | 0.7706 | 6.13 | 0.2896 | 7.84 | -0.123 | 14.61 | -21.54 | 11.38 | 6.38 | 8.45 |
Jubilant Pharmova Ltd | 66.22bn | 378.60m | 109.35bn | 1.03k | 284.98 | -- | 18.66 | 1.65 | 2.42 | 2.42 | 415.43 | -- | -- | -- | -- | 64,045,440.00 | -- | 3.95 | -- | 4.78 | 67.64 | 66.57 | 0.5133 | 6.27 | -- | 1.36 | -- | 18.52 | 2.47 | -3.63 | -114.73 | -- | 10.74 | 10.76 |
Eris Lifesciences Ltd | 20.09bn | 3.92bn | 120.01bn | 3.55k | 30.65 | 4.64 | 20.70 | 5.97 | 28.78 | 28.78 | 147.52 | 190.12 | 0.375 | 2.37 | 5.62 | -- | 7.41 | 13.42 | 11.22 | 16.80 | 81.08 | 80.29 | 19.76 | 24.96 | 0.8345 | 5.80 | 0.4633 | -- | 19.23 | 15.39 | 2.57 | 6.15 | 27.72 | -- |
Concord Biotech Ltd | 10.17bn | 3.08bn | 150.73bn | -- | 48.94 | 9.87 | 41.67 | 14.82 | 29.44 | 29.44 | 97.17 | 145.93 | -- | -- | -- | -- | -- | -- | -- | -- | 77.46 | -- | 30.30 | -- | 4.84 | -- | 0.0063 | -- | 19.20 | -- | 28.33 | -- | -- | -- |
Astrazeneca Pharma India Ltd | 11.97bn | 1.39bn | 160.82bn | 947.00 | 115.46 | -- | 103.94 | 13.43 | 55.72 | 55.72 | 478.78 | -- | -- | -- | -- | 12,640,230.00 | -- | 10.51 | -- | 18.10 | 59.93 | 58.05 | 11.64 | 9.11 | -- | 132.84 | -- | 11.82 | 24.50 | 11.89 | 61.19 | 30.82 | 6.29 | -- |
Suven Pharmaceuticals Ltd | 11.68bn | 3.71bn | 161.55bn | 1.17k | 43.54 | -- | 38.46 | 13.83 | 14.58 | 14.58 | 45.91 | -- | -- | -- | -- | 10,023,860.00 | -- | -- | -- | -- | 58.68 | -- | 31.76 | -- | -- | 86.09 | -- | -- | 1.52 | -- | -9.37 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 15 Dec 2023 | 6.98m | 5.13% |
UTI Asset Management Co. Ltd. (Investment Management)as of 03 May 2024 | 6.78m | 4.98% |
Franklin Templeton Asset Management (India) Pvt Ltd.as of 15 May 2024 | 1.99m | 1.46% |
Templeton Asset Management Ltd.as of 30 Apr 2024 | 1.78m | 1.31% |
Plutus Wealth Management LLPas of 30 Sep 2023 | 1.50m | 1.10% |
Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 30 Apr 2024 | 1.18m | 0.87% |
HSBC Asset Management (India) Pvt Ltd.as of 30 Apr 2024 | 762.58k | 0.56% |
Tata Asset Management Ltd.as of 30 Apr 2024 | 535.44k | 0.39% |
Bank of India Investment Managers Pvt Ltd.as of 30 Apr 2024 | 503.71k | 0.37% |
Dimensional Fund Advisors LPas of 09 May 2024 | 402.67k | 0.30% |